GlassScriptPhysician profile
Matthew Lesneski
NPI 1720240369
$46,813.99
in general payments reported to CMS, 2019-2025
50 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,154 · 2020: $5,523 · 2021: $3,438 · 2022: $3,138 · 2023: $1,773 · 2024: $1,724 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $6,963 · Food and Beverage: $5,363 · Travel and Lodging: $1,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,865.00 |
| Consulting Fee | $6,963.00 |
| Food and Beverage | $5,362.67 |
| Travel and Lodging | $1,370.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $20,793.27 | 2024-2025 | |
| Abbott Laboratories | $8,197.67 | 2019-2025 | Proclaim, Eterna, Octrode |
| Vertos Medical, INC. | $3,562.49 | 2019-2024 | Mild Device Kit |
| Mdd US Operations, LLC | $2,682.39 | 2019-2020 | |
| Arthrex, INC. | $2,017.00 | 2019 | |
| Vertiflex, INC. | $1,715.68 | 2019 | |
| Collegium Pharmaceutical, INC. | $1,457.65 | 2019-2025 | Belbuca, Xtampza |
| Surgentec | $930.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $698.64 | 2019-2025 | Relistor |
| Nevro Corp. | $622.78 | 2019-2024 | Senza |
| Liberty Surgical INC. | $514.33 | 2019 | |
| Scilex Pharmaceuticals INC. | $410.05 | 2019-2025 | Ztlido |
| Medtronic, INC. | $273.31 | 2021-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Accurian |
| Boston Scientific Corporation | $272.66 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Foundation Fusion Solutions, LLC | $260.19 | 2021-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Lesneski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.